My watch list
my.chemeurope.com  
Login  

Budesonide



Budesonide
Systematic (IUPAC) name
16,17-(butylidenebis(oxy))-11,21-dihydroxy-, (11-β,16-α)-pregna-1,4-diene-3,20-dione
Identifiers
CAS number 51333-22-3
ATC code A07EA06 D07AC09, R01AD05, R03BA02
PubChem 63006
DrugBank APRD00442
Chemical data
Formula C25H34O6 
Mol. mass 430.534 g/mol
Pharmacokinetic data
Bioavailability 100% (but large first pass effect)
Protein binding 85-90%
Metabolism Hepatic CYP3A4
Half life 2.0-3.6 hours
Excretion Renal, Faecal
Therapeutic considerations
Pregnancy cat.

C(US)

Legal status

POM(UK)

Routes Oral, Nasal, tracheal, rectal

Budesonide is a glucocorticoid steroid for the treatment of asthma, non-infectious rhinitis (including hay fever and other allergies), and for treatment and prevention of nasal polyposis. Additionally, it is used for inflammatory bowel disease. It is marketed by AstraZeneca as a nasal inhalation with the brand name Rhinocort (in Denmark, as Rhinosol), as an oral inhalation with the brand name Pulmicort, and as an enema and a modified-release capsule with the brand name Entocort. It is also sold in combination with formoterol (Oxis) in a single inhaler, with the brand name Symbicort.

Additional recommended knowledge

Pharmacology

Budesonide has a high first pass metabolism. It has efficacy in the terminal ileum and the right colon. Budesonide in comparison with prednisolone has been associated with fewer bone density losses and unlike other corticosteroids has little influence on the hypothalamic-pituitary-adrenal axis which also limit the need of tapering before discontinuation. Overall, it has a lower incidence of systemic manifestations than similar medications.

Side Effects

Budesonide may cause:

  • nose irritation or burning
  • bleeding or sores in the nose
  • lightheadedness
  • upset stomach
  • cough
  • hoarseness
  • dry mouth

In addition the following should be reported:

  • Immediately if difficulty breathing or swelling of the face
  • white patches in the throat, mouth, or nose
  • irregular menstrual periods
  • severe acne


Recall

Pulmicort inhalers were recalled in 2002 because there was concern that they may not always have provided the full dosage.

 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Budesonide". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE